Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- PI for Sancuso Completed in Japanese Volunteers: Solasia
November 23, 2009
- Merck's Merger with Schering-Plough Completed
November 23, 2009
- Avastin Approved for NSCLC in Japan: Chugai
November 23, 2009
- Yakult Aims at ¥10 Bil. Sales for Elplat with Stomach Cancer
November 23, 2009
- Sanofi-aventis, Micromet Sign License Agreement for BiTE Antibody
November 23, 2009
- Fludara Obtains Different Additional Indications for Tablet and Injectable
November 23, 2009
- Astellas to Overcome Prograf, Harnal Patent Expiration with New Products: President Nogimori
November 23, 2009
- Daiichi Sankyo Terminates Levofloxacin Patent Litigation
November 23, 2009
- Farletuzumab to Be Applied for in FY2012 in US: Eisai
November 23, 2009
- Santen: License Fees Boost Operating Profits Up 237%
November 23, 2009
- Freund Creates Subsidiary in Europe
November 23, 2009
- Subcutaneous Velcade in PIII in US: Takeda
November 23, 2009
- Kissei: Sales Driven by Urief
November 23, 2009
- NHI Price Listing for 394 Generic Products Announced
November 23, 2009
- Nexavar Enters PIII for Non-Responsive Thyroid Cancer: Bayer, Onyx
November 23, 2009
- Nippon Shinyaku: Sales Down 5.9%
November 23, 2009
- Strong Growth in Sales, Profits Reported by Top-4 Generic Makers
November 23, 2009
- Kyorin: Sales Up 13.5% Driven by Kipres
November 23, 2009
- Zeria: Sales Up Driven by OTC Drugs
November 23, 2009
- Half-year Business Results for Leading Generic Makers
November 23, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…